S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia

Postmenopausal patients with metastatic breast cancer (mBC) may live years with their disease on therapies with minimal toxicities but they will eventually progress on first-line therapy. For those eligible for second-line therapy, PIK3CA mutation testing is recommended in estrogen receptor–positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Katharine, Germain, Monique, Loch, Michelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210085/
https://www.ncbi.nlm.nih.gov/pubmed/35712858
http://dx.doi.org/10.1177/23247096221105249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210085/
https://www.ncbi.nlm.nih.gov/pubmed/35712858
http://dx.doi.org/10.1177/23247096221105249

Ejemplares similares